The stock of HilleVax Inc (NASDAQ: HLVX) has decreased by -2.37% when compared to last closing price of $2.11. Despite this, the company has experienced a 5.64% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-08 that $159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates inadults as well as business development related activities and other strategic alternatives BOSTON, May 08, 2025 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2025. First Quarter Financial Results As of March 31, 2025 and December 31, 2024, the company had cash, cash equivalents and marketable securities totaling $159.5 million and $171.4 million, respectively.
Is It Worth Investing in HilleVax Inc (NASDAQ: HLVX) Right Now?
Additionally, the 36-month beta value for HLVX is 0.75. There are mixed opinions on the stock, with 0 analysts rating it as a “buy”, 0 rating it as “overweight”, 2 rating it as “hold”, and 0 rating it as “sell”.
The public float for HLVX is 22.74M and currently, short sellers hold a 7.12% ratio of that float. The average trading volume of HLVX on July 04, 2025 was 333.52K shares.
HLVX’s Market Performance
HLVX stock saw an increase of 5.64% in the past week, with a monthly gain of 5.10% and a quarterly increase of 37.33%. The volatility ratio for the week is 4.91%, and the volatility levels for the last 30 days are 4.37% for HilleVax Inc (HLVX). The simple moving average for the past 20 days is 5.91% for HLVX’s stock, with a 11.26% simple moving average for the past 200 days.
Analysts’ Opinion of HLVX
Many brokerage firms have already submitted their reports for HLVX stocks, with Stifel repeating the rating for HLVX by listing it as a “Hold”. The predicted price for HLVX in the upcoming period, according to Stifel is $3 based on the research report published on July 09, 2024 of the previous year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see HLVX reach a price target of $2, previously predicting the price at $28. The rating they have provided for HLVX stocks is “Market Perform” according to the report published on July 09th, 2024.
JP Morgan gave a rating of “Neutral” to HLVX, setting the target price at $5 in the report published on July 08th of the previous year.
HLVX Trading at 7.19% from the 50-Day Moving Average
After a stumble in the market that brought HLVX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.72% of loss for the given period.
Volatility was left at 4.37%, however, over the last 30 days, the volatility rate increased by 4.91%, as shares surge +4.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.73% upper at present.
During the last 5 trading sessions, HLVX rose by +5.64%, which changed the moving average for the period of 200-days by +12.57% in comparison to the 20-day moving average, which settled at $1.95. In addition, HilleVax Inc saw -85.71% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HLVX starting from HERSHBERG ROBERT, who sold 14,634 shares at the price of $1.89 back on Feb 04 ’25. After this action, HERSHBERG ROBERT now owns 1,113,399 shares of HilleVax Inc, valued at $27,658 using the latest closing price.
HERSHBERG ROBERT, the of HilleVax Inc, sale 11,901 shares at $1.76 during a trade that took place back on Feb 11 ’25, which means that HERSHBERG ROBERT is holding 1,101,498 shares at $21,003 based on the most recent closing price.
Stock Fundamentals for HLVX
The total capital return value is set at -0.61%. Equity return is now at value -54.64%, with -43.20% for asset returns.
Based on HilleVax Inc (HLVX), the company’s capital structure generated 0.14 points at debt to capital in total, while cash flow to debt ratio is standing at -3.68. The debt to equity ratio resting at 0.16. The interest coverage ratio of the stock is -40.47.
Currently, EBITDA for the company is -155.29 million with net debt to EBITDA at 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 25.32.
Conclusion
In conclusion, HilleVax Inc (HLVX) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
